The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine for adults 18 and over.

The EUA is for the two-dose primary series targeting the original Wuhan SARS-CoV-2 virus — limiting the vaccine’s use, as about two-thirds of Americans already have completed a primary series of either the Pfizer, Moderna or Johnson & Johnson vaccines.

The Centers for Disease Control and Prevention (CDC) still needs to sign off on the Novavax vaccine before pharmacies and other healthcare providers can start administering shots.

The vaccine maker’s stock rose 3% earlier today, after Politico reported yesterday that the FDA would likely announce the decision today.

The Biden administration on Monday announced a deal with Novavax to purchase 3.2 million doses of the vaccine.

Under the taxpayer-funded deal — which the U.S. Department of Health and Human Services said was contingent on the vaccine receiving EUA and formal recommendation by the Centers for Disease Control and Prevention — the U.S. government will provide the vaccine to states, jurisdictions, federal pharmacy partners and federally qualified health centers.